Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan

Sen. Elizabeth Warren and Rep. Jan Schakowsky are challenging Pfizer, Merck, Johnson & Johnson, AbbVie, and Amgen regarding their low tax payments, alleging they utilize offshore subsidiaries to avoid U.S. taxes despite substantial profits. The lawmakers question whether lobbying efforts by these companies aim to preserve tax loopholes within the GOP's reconciliation bill, which could extend tax cuts from the 2017 Tax Cuts and Jobs Act. The inquiry coincides with ongoing debates about pharmaceutical pricing and potential tax reforms, with Democrats seeking to build public opposition to extending tax breaks for the industry.

Analysis

Intensified scrutiny from Democratic lawmakers targets five major pharmaceutical companies—Pfizer, Merck, Johnson & Johnson, AbbVie, and Amgen—over their U.S. tax contributions, with allegations of utilizing offshore subsidiaries in low-tax jurisdictions, such as Ireland and Bermuda, to minimize tax on substantial profits. This practice is linked to provisions in the 2017 Tax Cuts and Jobs Act, which a current GOP reconciliation bill may make permanent, prompting inquiries into corporate lobbying efforts, exemplified by Johnson & Johnson's reported $150,000 spending on international tax issues in Q4 2024. The Council on Foreign Relations estimates that reforming this offshore tax loophole could generate at least $100 billion in U.S. tax revenue over ten years. This scrutiny echoes past investigations, such as one accusing Pfizer of avoiding U.S. income tax on $20 billion in 2019 domestic drug sales, a claim Pfizer refutes by citing $12.8 billion in U.S. taxes paid over four years. The ongoing situation, marked by a strongly negative sentiment (overall score -0.65, with Pfizer at -0.8), introduces significant political and regulatory risk for these firms, interwoven with broader debates on drug pricing and corporate tax equity.

Key Decisions for Investors

• Investors should closely monitor legislative developments concerning the GOP reconciliation bill and any proposed changes to corporate tax provisions, particularly those affecting multinational profit-shifting.
• It is advisable to assess the potential impact on the effective tax rates and net income of Pfizer, Merck, Johnson & Johnson, AbbVie, and Amgen should current tax loopholes be closed or significantly altered.
• Consider the heightened headline risk and sustained negative sentiment, indicated by a general score of -0.65 and specific ticker scores ranging from -0.6 to -0.8, which could pressure stock valuations of the implicated pharmaceutical companies pending the outcome of these inquiries and legislative actions.
• Evaluate the companies' disclosures and responses to these allegations, with lawmakers requesting replies by July 1, for insights into their tax strategies and potential future liabilities.